Willow Review

• Four published GLP-1 routes — weekly injection or daily tablet, single-agonist or dual-action
• Per-treatment pricing from $199/month (NAD+), $299 (semaglutide) and $399 (tirzepatide), each including medication, evaluation, unlimited doctor access and shipping
• Unusually complete regulatory disclosure, including USP compounding standards and a not-brand-equivalent statement
• Free two-day shipping and free regular follow-ups
• FSA and HSA eligible; no insurance required
• Displays a LegitScript seal linking to LegitScript's own verification checker (checked 16 September 2026)

Compounded semaglutide as a weekly injection or a daily tablet, compounded tirzepatide as a weekly injection or a daily tablet, and NAD+. Prescribed only where an independent licensed physician judges treatment appropriate. Willow states that compounded medications, including compounded semaglutide, tirzepatide and NAD+, are not approved by the FDA and are not reviewed by the FDA for safety, effectiveness or quality.

Free online assessment, with Willow stating that a US-licensed doctor reviews and confirms the prescription the same day. Free regular follow-ups with the care team are included.

Free two-day, discreet shipping is included in the monthly price.

Willow sells compounded semaglutide in two forms at the same price. The once-weekly injection is $299 a month, and the daily sublingual tablet is also $299 a month (checked 16 September 2026). That parity is the notable part: most platforms in this segment either do not offer an oral route at all or charge a premium for it, and Willow does neither. If the needle is the obstacle, it costs you nothing to avoid it here.

Willow describes the tablet as "administered via daily doses under the tongue", absorbed through the tissue rather than swallowed, and frames it as "a popular alternative for patients that are uncomfortable with self-injections". It does not claim the two routes are equivalent, and this page will not supply a claim it has not made — which route suits a given person is a clinical judgement for the prescribing doctor, not something a directory can rank.

Both pages carry the same inclusions and the same regulatory wording: "In stock: Same day prescriptions and free 2-Day shipping", each batch quality-tested, and "compounded semaglutide is not approved by the FDA, and the FDA does not review compounded medications for safety, effectiveness, or quality". Semaglutide acts on the GLP-1 receptor alone, which is the distinction from the dual-agonist option below.

Compounded tirzepatide is $399 a month as a weekly injection — $100 more than semaglutide, or $1,200 more across a year. Willow also lists a daily tirzepatide tablet at the same $399, described as "travel-friendly, no refrigeration needed", though that route has no dedicated tracked link here and is reached through the main Willow page.

Tirzepatide is a dual agonist: it acts on both the GLP-1 and the GIP receptor, where semaglutide acts on GLP-1 alone. Willow describes it as "a next-generation dual agonist that targets both GLP-1 and GIP receptors to help regulate appetite, support metabolic balance, and may support weight loss" — note its own hedge, "may support". Whether the second pathway is worth $100 a month to you is exactly the kind of question the prescribing doctor is for.

The same caveats apply as to every compounded product on the platform. Willow states that compounded tirzepatide "is not approved by the FDA", that it is prepared by state-licensed compounding pharmacies meeting USP standards, and — the sentence most worth reading twice — that compounded medications "are not brand-equivalent".

NAD+ is the cheapest thing Willow sells, at $199 a month, and the only item on its menu that is not a weight-loss treatment. Willow does not present it as one: its page is framed around energy, focus and skin rather than weight, and it sits under Treatments alongside the four GLP-1 routes rather than in a separate wellness section — which does blur the two.

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell, involved in energy metabolism and cellular repair, whose levels are generally thought to decline with age. That is why it appears so heavily in longevity marketing. It is a naturally occurring molecule rather than an approved anti-ageing medicine, and the human evidence behind the energy, focus and recovery claims made around it remains limited.

Willow's own regulatory footer explicitly includes compounded NAD+ among the medicines that "are not approved by the FDA". Treat the page's benefit language as marketing and the decision as a clinical one.

Willow's regulatory disclosure is the most complete of the programmes reviewed here, and worth quoting because the detail is the point. It states that "compounded medications (including compounded semaglutide, tirzepatide, and NAD+) are not approved by the FDA, and the FDA does not review compounded medications for safety, effectiveness, or quality". It then goes further than its competitors: "these medications are prepared by state-licensed compounding pharmacies that operate under state board of pharmacy oversight and are required to meet USP compounding standards."

Two further statements do real work. "Compounded medications are not brand-equivalent" addresses the most common misconception in this market — that a compounded preparation is a generic version of an approved product, which it is not. And "Willow is not the compounding pharmacy or manufacturer" makes the structure explicit: Willow is a telehealth platform connecting patients with independent licensed physicians, not the maker or dispenser of the medicine.

Willow also states that "prescription product availability varies by state", and carries a plain risk statement directing patients to the risk information on each product page and to a conversation with their doctor. What it does not publish is the name of any compounding pharmacy, or any refund or cancellation terms — a terms-of-service page exists, but the commercial terms inside it are not summarised anywhere a prospective buyer can read them before paying.

Willow is the only programme on this list that prices each treatment separately, and the only one publishing a needle-free route at the same price as the injection. Against TrimRx, which publishes two tiers at $179 and $259 and states its price holds as the dose rises, Willow's semaglutide is more expensive at $299 but its oral option has no equivalent there. Against MEDVi at $179, the same gap applies.

Against Trimi the comparison inverts depending on commitment. Trimi's $99 semaglutide and $125 tirzepatide are annual equivalents requiring $1,188 or $1,500 upfront; its month-to-month rates are $175 and $235. Willow asks for no year in advance, so it is dearer than Trimi's annual plan and dearer than its monthly one too — Willow's premium is for choice of route and for unlimited doctor access, not for flexibility.

What none of these can be separated on is results. Each publishes outcome figures or testimonials on its own marketing pages and each qualifies them in its own small print; Willow's states that "individual results may vary and are not guaranteed". The comparable facts are price structure, what a price includes, who prescribes, what is published about the pharmacy, and what happens if you stop — and on the last two Willow publishes least.

PCF reviews online programs for comparison purposes only. Provider details, pricing, availability, and medication paths can change. Confirm current terms directly and consult a licensed clinician before making medical decisions.